{"id":"NCT05045144","sponsor":"GlaxoSmithKline","briefTitle":"A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.","officialTitle":"A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-26","primaryCompletion":"2022-06-06","completion":"2022-06-06","firstPosted":"2021-09-16","resultsPosted":"2023-10-05","lastUpdate":"2023-10-05"},"enrollment":1586,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"RSVPreF3(120 μg)","otherNames":[]},{"type":"COMBINATION_PRODUCT","name":"Flu Quadrivalent influenza vaccine (15 μg HA)","otherNames":[]},{"type":"COMBINATION_PRODUCT","name":"Placebo","otherNames":[]}],"arms":[{"label":"RSV lot1 Group","type":"EXPERIMENTAL"},{"label":"RSV lot2 Group","type":"EXPERIMENTAL"},{"label":"RSV lot3 Group","type":"EXPERIMENTAL"},{"label":"RSV+Flu pooled Group","type":"EXPERIMENTAL"},{"label":"Flu+Placebo Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the clinical lot-to-lot consistency of the respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine administered to healthy non-pregnant women 18-49 years of age (YOA). In addition, this study will evaluate immunogenicity, safety and reactogenicity from co-administration of RSV MAT vaccine and GSK's quadrivalent seasonal influenza (Flu D-QIV) vaccine.","primaryOutcome":{"measure":"Percentage of Participants Reporting Solicited Administration Site Events in RSV Pooled Group, RSV+Flu Pooled Group and Flu+Placebo Group","timeFrame":"From Day 1 to Day 7 (including Day 7)","effectByArm":[{"arm":"RSV Pooled Group","deltaMin":53.6,"sd":null},{"arm":"RSV+Flu Pooled Group","deltaMin":51.1,"sd":null},{"arm":"Flu+Placebo Group","deltaMin":34.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":22},"locations":{"siteCount":36,"countries":["United States","Canada","Finland","South Korea","Spain"]},"refs":{"pmids":["38970327"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":220},"commonTop":["Administration site pain","Fatigue","Headache","Nausea","Diarrhoea"]}}